Evidence mapPaperPMID 41782033Full record

ReviewJournal of translational medicine2026

The value of targeting ketone body metabolism in inflammatory and autoimmune diseases.

Yanmei Gong, Yifan Wei, Ying Liu, Tong Du

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yanmei GongDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, People's Republic of China.
Yifan WeiDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, People's Republic of China.
Ying LiuDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, People's Republic of China. drliuying2020@163.com.
Tong DuDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, People's Republic of China. dutong1992@hotmail.com.ORCID http://orcid.org/0000-0002-9588-8326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKetone body metabolism has gained increasing attention as a key regulator of immunometabolic homeostasis. Beyond serving as alternative energy substrates during fasting or ketogenic states, ketone bodies—particularly β-hydroxybutyrate—function as signaling molecules capable of modulating inflammation and immune responses. Emerging evidence suggests that ketone body–mediated immunoregulation may have significant therapeutic implications for autoimmune and inflammatory disorders. However, the underlying mechanisms and translational potential of targeting ketone body metabolism have not yet been comprehensively summarized. MAIN BODY: This review provides an integrated overview of the molecular and cellular mechanisms through which ketone bodies influence immune function. We discuss how β-hydroxybutyrate regulates macrophages and T cells via inhibition of the NOD-like receptor pyrin domain–containing 3 (NLRP3) inflammasome, activation of hydroxycarboxylic acid receptor 2 (HCAR2), and epigenetic reprogramming including histone β-hydroxybutyrylation. Furthermore, we examine current strategies for modulating ketone body metabolism, including the ketogenic diet, exogenous ketone supplementation, sodium–glucose cotransporter 2 inhibitors, and metabolic enzyme regulators. Preclinical studies and early clinical evidence indicate potential anti-inflammatory and immunomodulatory benefits of these interventions in diseases such as multiple sclerosis, inflammatory bowel disease, gout, metabolic dysfunction–associated steatohepatitis, and atherosclerosis.

conclusionsCollectively, current findings support ketone body metabolism as a promising therapeutic target within the field of immunometabolism. Modulation of ketone body pathways may offer novel strategies for controlling chronic inflammation and autoimmune pathology. Future studies are required to optimize intervention protocols, clarify long-term safety, and bridge the gap between basic mechanistic research and clinical translation.

Indexed as

Autoimmune DiseasesInflammationKetone BodiesAnimalsHumansKetone BodiesAutoimmune diseasesImmunometabolismInflammatory diseasesKetogenic dietKetone bodies

Identifiers

PMID41782033
PMCPMC13097814

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.